Foghorn Therapeutics Inc.
06/26/2024 | Press release | Distributed by Public on 06/26/2024 14:05
Submission of Matters to a Vote of Security Holders Form 8 K
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 26, 2024, Foghorn Therapeutics Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The following proposals were submitted to the Company's stockholders at the Annual Meeting:
(i) To elect Scott Biller, Ph.D., Thomas J. Lynch, M.D., and Michael Mendelsohn, M.D., as Class I directors, each for a three-year term; and
(ii) To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.
The proposals are described in detail in the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on May 3, 2024.
The number of shares of common stock entitled to vote at the Annual Meeting was 42,585,616. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 30,381,145. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.
The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:
(i) Election of directors.
|
Director Nominee
|
Votes For
|
Votes Against
|
Abstentions
|
|
Scott Biller, Ph.D.
|
20,425,665 | 4,930,514 | 10,337 |
|
Thomas J. Lynch, M.D.
|
24,052,377 | 1,293,218 | 20,921 |
| Michael Mendelsohn, M.D. | 22,357,558 | 2,988,038 | 20,920 |
There were 5,014,629 broker non-votes regarding the election of directors.
(ii) Ratification of selection of independent registered public accounting firm.
Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the voting included 30,355,319 votes for, 10,376 votes against and 15,450 abstentions. There were no broker non-votes regarding this proposal.